Videos

W. David Hardy, MD, discusses the Undetectable Equals Untransmittable (U=U) movement.

Ian Frank, MD, discusses the future of HIV prevention and long-acting injectables.

Paul Sax, MD, discusses 2-drug approaches for treatment of HIV, including dolutegravir + lamivudine.

W. David Hardy, MD, discusses how important access to PrEP is for people at high risk of contracting HIV.

Ian Frank, MD discusses how younger individuals who do not take regular medication may struggle to adhere to the daily routine.

Paul Sax, MD, discusses treatments for HIV that are currently in development.

W. David Hardy, MD, discusses the challenges health care providers encounter when it comes to patients taking PrEP.

Ian Frank, MD, discusses strategies that individuals taking PrEP can use to maintain adherence to the daily regimen.

Sharon Tsay, MD, explains why burden estimates for candidemia are needed.

Emily Ricotta, PhD, ScM, highlights the increase in non-albicans candidiasis, which tends to be more antibiotic resistan,t in both bloodstream and sterile-site infections.

Mitsuru Toda, MS, PhD, discusses research that discovered 94 patients who had invasive aspergillosis with influenza.

Melvin Weinstein MD, discusses the emerging technologies that will advance the field of blood culture testing.

Julie Ann Justo, PharmD, discusses the myths associated with penicillin allergies and why it is important to determine a patient's true penicillin allergy-status.

Kenneth Sherman, MD, discusses hepatitis B infections in immunocompromised patients and what clinicians should expect to see in the future for hepatitis B treatment.

Norman Javitt, MD, PhD, discusses the concept of using ursodeoxycholic acid and its potential role in suppressing C diff spores to prevent inflammation.

Maureen Spencer, RN, M.Ed., discusses how rapid molecular diagnostics are changing the treatment timeline for sepsis and Clostridium difficile (C diff).

Edmund A. Hooker, MD, DrPH, discussed the gaps in disinfection in the hospital and how hospital beds can be properly sanitized to prevent the spread healthcare-associatedted infections.

Mike Ison, MD, MS, discusses the key takeaways from the CAPSTONE-2 phase 3 trial evaluating baloxavir marboxil for the treatment of patients with influenza.

Kenneth E. Sherman, MD discusses the zoonotic hepatitis E virus and about the first reported case of rat-to-human transmission.

Jason Gallagher, PharmD, discusses how omadacycline could potentially replace fluoroquinolone use in the treatment of complicated skin infections and community-acquired pneumonia.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, provides examples from her institution about using prediction scores and rapid diagnostic scores in concert.

Mindy Smith, BSPharm, RPh, provides tips for recommending the flu shot to patients who are more likely to get the flu.

Dale N Gerding, MD, provides insight about prevention options for C diff that are expected in the future.

Colleen Kelley, MD, discusses the possibility of an HIV vaccine and current progress being made in HIV prevention.

Nimish Patel, PharmD, PhD, describes his study, which compared fidaxomicin with oral vancomycin in early targeted therapy of C diff.

Dale N. Gerding, MD, discusses bezlotoxumab and its use for preventing recurrent C diff infections.

Douglas Krakower, MD, explains how predictive models can be used to identify patients that are at a higher risk for HIV and could benefit from learning about PrEP.

Eric Daar, MD, discusses the obstacles associated with new research and technology in the pursuit of finding a cure for HIV.

Yoav Golan, MD, discusses the paradigm shift occurring in treatment for ABSSSI and how to motivate clinicians to buy into new programs and protocols.

Panelists hypothesize on theoretical downsides of resistance development for gram-negative infections and reflect on the importance of implementing outpatient parenteral antibiotic therapy.